Discovering and developing innovative therapeutics for CNS disorders

Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SWX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.

Latest Press Releases

Newron acquisition of Hunter-Fleming. Upfront payment agreed.

29/04/2008
English ENG  German GER

Newron shareholders’ meeting

25/04/2008
English ENG  German GER

Investor News

Current Share Price:
31.40

Currency:
CHF

Last Close:
31.40

Change:
-1.10